LIFEWORKS
8.9.2021 11:02:06 CEST | Business Wire | Press release
LifeWorks, a leading provider of digital and in-person total wellbeing solutions, has announced the acquisition of Ascender, a leading psychological services provider in the field of employee health and wellbeing.
Key highlights of the acquisition include:
- Headquartered in the Netherlands, Ascender’s highly experienced team of 38 employees and approximately 40 freelancers will join LifeWorks and continue to operate out of its 25 locations across the Netherlands, with existing clients seeing their services continue uninterrupted.
- As Ascender is integrated into LifeWorks global operations, it will operate in the Netherlands on a largely standalone basis, servicing clients throughout the Benelux region.
- Ascender operated first as a combination of network partners 25 years ago and merged to become Ascender in 2009. It is one of the most respected providers in the corporate wellbeing market in the Netherlands and has a strong roster of approximately 150 clients with an average tenure of 10 years.
- The acquisition will leverage the skills, knowledge and experience Ascender’s teams and services that include psychological services related to health@work, employee assistance programmes, counselling, and training through a team of highly credentialed psychologists, while giving Ascender access to LifeWorks clinical best practices, digital technology and worldwide presence.
- With Ascender’s strong track record of growth, local knowledge and clinical expertise, the move will allow LifeWorks to continue to expand its total wellbeing solutions to domestic European markets, and harness its existing relationships with insurance providers, hospitals and care companies as well as (multi)nationals working out of the Netherlands post-Brexit.
Comments from Philip Mullen, managing director, United Kingdom and Europe at LifeWorks:
“Throughout the pandemic we have witnessed a huge appetite amongst multinationals and local companies to support the total wellbeing of employees that are now spread across the world. The acquisition of Ascender will not only strengthen our presence in this region, but in addition, given Ascender offers a full suite of clinical expertise and research, our hope is that the company’s insight on psychological wellbeing can further enhance our customer offering on a global level.”
Comments from Moniek Vossenaar, managing director, Ascender:
“Joining LifeWorks represents an important step for Ascender’s growth, the services we provide and the opportunities for our employees. The companies have a shared goal to improve the total wellbeing of our clients’ employees, and shared values of long-term relationships, treating others the way we want to be treated, and being innovative and entrepreneurial. We’re positive this acquisition will be beneficial to both companies and all parties involved.”
This acquisition represents approximately one per cent of LifeWorks revenue and is not expected to have a material impact on the company’s financial performance in 2021.
About LifeWorks
LifeWorks is a world leader in providing digital and in-person solutions that support the total wellbeing of individuals. We deliver a personalised continuum of care that helps our clients improve the lives of their people and by doing so, improve their business.
About Ascender
Founded in 2009, Ascender is one of the top three players in the corporate wellness market in the Netherlands and has a strong roster of approximately 150 clients with an average tenure of 10 years. Headquartered in the Netherlands, Ascender hash 25 locations across the country, 38 employees and approximately 40 freelancers. The company offers psychological services related to health@work, EFAP, counselling, and training/coaching through a team of psychologists, on a fee for service basis.
ID-CORP, ID-MH, ID-UK
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005404/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
